$Targeted therapy and hematopoietic stem cell transplantation for relapsed/refractory Hodgkin lymphoma in pediatric and adolescent patients: a pilot protocol results$

Targeted therapy and hematopoietic stem cell transplantation for relapsed/refractory Hodgkin lymphoma in pediatric and adolescent patients: a pilot protocol results

Background. Introduction a targeted drugs in a real clinical practice bring a vast improvement of prognosis in patients with relapsed and refractory (r/r) Hodgkin lymphoma (HL). But it is necessary to increase the experience in anti-CD30 monoclonal antibodies in combination with second-line chemothe...

Full description

Bibliographic Details
Main Authors:	Natalia S. Tsaplina, Timur T. Valiev, Kirill I. Kirgizov, Svetlana R. Varfolomeeva
Format:	Article
Language:	Russian
Published:	IP Habib O.N. 2023-05-01
Series:	Современная онкология
Subjects:	hodgkin lymphoma relapse refractory brentuximab vedotin treatment children adolescents
Online Access:	https://modernonco.orscience.ru/1815-1434/article/viewFile/271831/pdf

Similar Items

Modern approaches in relapsed and refractory Hodgkin lymphoma treatment: literature review and own experience
by: Natalia S. Tsaplina, et al.
Published: (2022-11-01)

Novel Agents For Relapsed and Refractory Classical Hodgkin Lymphoma: A Review
by: Yujie Zhang, et al.
Published: (2022-07-01)

Brentuximab vedotin in the treatment of relapsed and refractory forms of Hodgkin lymphoma
by: E A Demina
Published: (2016-06-01)

Immunotherapy in Hodgkin Lymphoma: Present Status and Future Strategies
by: Theodoros P. Vassilakopoulos, et al.
Published: (2019-07-01)

TREATMENT OF RELAPSE AND REFRACTORY HODGKIN LYMPHOMA
by: E. A. Baryakh
Published: (2017-06-01)

Optimizing Treatment for Relapsed/Refractory Classic Hodgkin Lymphoma in the Era of Immunotherapy
by: Michael P. Randall, et al.
Published: (2023-09-01)

The role of radiotherapy in patients with refractory Hodgkin's lymphoma after treatment with brentuximab vedotin and/or immune checkpoint inhibitors
by: Ruizhi Zhao, et al.
Published: (2024-03-01)

Successful brentuximab vedotin monotherapy against late relapse of classical Hodgkin lymphoma 6 years after first remission
by: Kana Nagashima, et al.
Published: (2020-03-01)

The Role of Brentuximab Vedotin (BV) as Second-Line Treatment of Refractory Classical Hodgkin Lymphoma (cHL) in the Era of Pandemic COVID-19
by: Rajabto W, et al.
Published: (2022-06-01)

Novel Salvage Therapy Options for Initial Treatment of Relapsed/Refractory Classical Hodgkin’s Lymphoma: So Many Options, How to Choose?
by: Radhika Takiar, et al.
Published: (2022-07-01)

Pharmacoeconomic analysis of therapy with brentuximab vedotin, nivolumab and pembrolizumab in patients with relapsed Hodgkin’s lymphoma
by: N. A. Avxentyev, et al.
Published: (2020-12-01)

Therapeutic Updates for Relapsed and Refractory Classical Hodgkin Lymphoma
by: Timothy J Voorhees, et al.
Published: (2020-10-01)

Salvage Therapy for Hodgkin’s Lymphoma: A Review of Current Regimens and Outcomes
by: Castagna L, et al.
Published: (2020-10-01)

A case of metachronous peripheral T‐Cell non‐Hodgkin lymphoma following chemotherapy for Hodgkin disease successfully treated with brentuximab vedotin
by: Federico Meconi, et al.
Published: (2020-08-01)

Treatment of Hodgkin Lymphoma Relapsed after Autologous Stem Cell Transplantation
by: Eva Domingo-Domènech, et al.
Published: (2020-05-01)

Brentuximab vedotin is the first target drug in the treatment of hodgkin lymphoma
by: G. S. Tumyan
Published: (2018-11-01)

TARGETED THERAPY WITH BRENTUXIMAB VEDOTIN IN RELAPSED AND REFRACTORY FORMS OF CLASSICAL HODGKIN LYMPHOMA
by: E. A. Demina
Published: (2017-11-01)

Brentuximab vedotin in children and adolescents with Hodgkin’s lymphoma and anaplastic large cell lymphoma – literature review and own experience
by: N. V. Myakova, et al.
Published: (2016-03-01)

Remission of relapsed/refractory classical Hodgkin lymphoma induced by brentuximab vedotin and pembrolizumab combination after allogeneic hematopoietic stem cell transplantation: a case report
by: Federica Giannotti, et al.
Published: (2024-03-01)

Use of ifosfamide, carboplatin and etoposide in combination with brentuximab vedotin or romidepsin based on CD30 positivity in relapsed/refractory peripheral T‐cell lymphoma
by: Cesar Gentille, et al.
Published: (2022-07-01)

COST-EFFECTIVENESS ANALYSIS OF BRENTUXIMAB VEDOTIN IN ADULTS WITH RELAPSED OR REFRACTORY HODGKIN’S LYMPHOMA
by: G. R. Khachatryan, et al.
Published: (2016-04-01)

Editorial: Advances in the treatment of Hodgkin lymphoma
by: Matthew Mei, et al.
Published: (2023-02-01)

Therapeutic response in patients with CD30+ lymphomas to biological therapy
by: Cakić Jelena, et al.
Published: (2020-01-01)

Safe prolonged use of brentuximab vedotin in a patient with Classical Hodgkin Lymphoma on hemodialysis
by: Aimee Schad, et al.
Published: (2023-09-01)

Cost-effectiveness of brentuximab vedotin in advanced stage Hodgkin’s lymphoma: a probabilistic analysis
by: A. J. N. Raymakers, et al.
Published: (2020-10-01)

Management of classical Hodgkin lymphoma: a look at up to date evidence and current treatment approaches
by: Walter Hanel, et al.
Published: (2022-12-01)

Pharmaceutical assessment of the rationale of the application of chemotherapy schemes containing immunotherapeutic drugs in the treatment of classical Hodgkin's lymphoma
by: M. R. Matushchak, et al.
Published: (2023-06-01)

Brentuximab vedotin plus AVD followed by involved-node radiotherapy in a patient with classic Hodgkin lymphoma following gray zone lymphoma after autologous stem-cell transplantation failure
by: Norihiro Ueda, et al.
Published: (2023-12-01)

How I Follow Hodgkin Lymphoma in First Complete (Metabolic) Remission?
by: Vibor Milunović
Published: (2024-02-01)

Brentuximab Vedotin and Pembrolizumab Combination in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Single-Centre Retrospective Analysis
by: Fulvio Massaro, et al.
Published: (2022-02-01)

Case Report: Brentuximab Vedotin Associated Acute Pancreatitis in a Pediatric Hodgkin Lymphoma Patient: Case Report and Literature Review
by: Ewelina Truszkowska, et al.
Published: (2022-08-01)

CLINICAL CHARACTERISTICS AND TREATMENT RESULTS OF PEDIATRIC RELAPSED/REFRACTORY NON-HODGKIN’S LYMPHOMAS
by: T. T. Valiev
Published: (2018-07-01)

Phase I clinical study of brentuximab vedotin (SGN-35) involving children with recurrent or refractory CD30-positive Hodgkin’s lymphoma or systemic anaplastic large cell lymphoma: rationale, design and methods of BV-HLALCL study: study protocol
by: Masahiro Sekimizu, et al.
Published: (2018-02-01)

Complete remission of Hodgkin’s lymphoma in a pediatric patient with TTN gene mutation treated with brentuximab vedotin combined chemotherapy without anthracyclines: A case report
by: Ying Li, et al.
Published: (2022-10-01)

Autologous Stem Cell Transplantation in Hodgkin Lymphoma—Latest Advances in the Era of Novel Therapies
by: Yazeed Samara, et al.
Published: (2022-03-01)

Current Treatment Options and the Role of Functional Status Assessment in Classical Hodgkin Lymphoma in Older Adults: A Review
by: Vittorio Ruggero Zilioli, et al.
Published: (2023-02-01)

Incorporating Monoclonal Antibodies into the First-Line Treatment of Classical Hodgkin Lymphoma
by: Theodoros P. Vassilakopoulos, et al.
Published: (2023-08-01)

Complete Remission of Relapsed Hodgkin’s Lymphoma following Brentuximab Vedotin and Gemcitabine Combination Therapy with Severe Hypotension as Possible Treatment-Related Adverse Event: A Case Report
by: Ibnu Purwanto, et al.
Published: (2020-03-01)

The Emerging Role of CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma
by: Jeremy A. Meier, et al.
Published: (2022-02-01)

Phase 2 study of everolimus for relapsed or refractory classical Hodgkin lymphoma
by: Patrick B. Johnston, et al.
Published: (2018-05-01)